• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

聚乙二醇干扰素-α治疗肝移植后慢性戊型肝炎病毒感染。

Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation.

机构信息

Department of Nephrology, Dialysis and Organ Transplantation, Centre Hospitalier Universitaire, Toulouse, France.

出版信息

Clin Infect Dis. 2010 Mar 1;50(5):e30-3. doi: 10.1086/650488.

DOI:10.1086/650488
PMID:20113176
Abstract

This study assessed the effect of a 3-month course of pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) in 3 liver transplant patients with chronic active hepatitis E. A virological response was sustained for 6 and 5 months in 2 patients after Peg-IFN-alpha-2a therapy was completed. A relapse was observed in the third patient.

摘要

本研究评估了 3 例慢性活动性戊型肝炎肝移植患者接受 3 个月聚乙二醇干扰素-α-2a（Peg-IFN-α-2a）治疗的效果。2 例患者在完成 Peg-IFN-α-2a 治疗后 6 个月和 5 个月时持续出现病毒学应答。第 3 例患者出现复发。

相似文献

1
Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation.聚乙二醇干扰素-α治疗肝移植后慢性戊型肝炎病毒感染。
Clin Infect Dis. 2010 Mar 1;50(5):e30-3. doi: 10.1086/650488.
2
Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient.聚乙二醇干扰素-α-2a 治疗血液透析患者慢性戊型肝炎病毒感染 3 个月。
Nephrol Dial Transplant. 2010 Aug;25(8):2792-5. doi: 10.1093/ndt/gfq282. Epub 2010 May 20.
3
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.聚乙二醇化α-干扰素-2a联合利巴韦林与聚乙二醇化α-干扰素-2b联合利巴韦林用于慢性丙型肝炎病毒的初始治疗：前瞻性、非随机研究。
J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.
4
Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients.在肾移植受者中，对于对利巴韦林耐药的慢性戊型肝炎病毒感染，可考虑使用聚乙二醇干扰素。
BMC Infect Dis. 2020 Jul 16;20(1):522. doi: 10.1186/s12879-020-05212-2.
5
[Pegylated interferon alpha 2a in treating chronic hepatitis B patients].
Zhonghua Gan Zang Bing Za Zhi. 2006 Nov;14(11):806-10.
6
Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.聚乙二醇化干扰素-α 2a用于慢性丙型肝炎病毒感染透析患者的初步研究。
Nephrology (Carlton). 2007 Feb;12(1):11-7. doi: 10.1111/j.1440-1797.2006.00662.x.
7
Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.聚乙二醇化干扰素α-2a联合利巴韦林递增剂量方案在肝移植后丙型肝炎病毒再感染早期阶段的疗效
Transpl Int. 2007 Jul;20(7):583-90. doi: 10.1111/j.1432-2277.2007.00481.x. Epub 2007 Apr 13.
8
[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].[匈牙利慢性乙型和丙型病毒性肝炎抗病毒治疗经验（1998 - 2004年）]
Orv Hetil. 2007 May 6;148(18):819-26. doi: 10.1556/OH.2007.28114.
9
[A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection].聚乙二醇化干扰素α治疗拉米夫定耐药慢性乙型肝炎病毒感染的病例报告
Korean J Hepatol. 2008 Dec;14(4):513-8. doi: 10.3350/kjhep.2008.14.4.513.
10
Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.聚乙二醇化干扰素α-2a与利巴韦林联合治疗丙型肝炎病毒肝移植受者：7例经验
J Gastrointestin Liver Dis. 2008 Jun;17(2):165-72.

引用本文的文献

1
Viral hepatitis E: Clinical manifestations, treatment, and prevention.戊型病毒性肝炎：临床表现、治疗与预防
Liver Res. 2024 Jan 6;8(1):11-21. doi: 10.1016/j.livres.2024.01.001. eCollection 2024 Mar.
2
Effect of Hepatitis E Virus on the Male Reproductive System: A Review of Current Evidence.戊型肝炎病毒对男性生殖系统的影响：现有证据综述
Viruses. 2025 Jan 5;17(1):66. doi: 10.3390/v17010066.
3
Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication.联合 RNA 干扰和 RIG-I 激活抑制戊型肝炎病毒复制。
Viruses. 2024 Aug 29;16(9):1378. doi: 10.3390/v16091378.
4
From discovery to treatment: tracing the path of hepatitis E virus.从发现到治疗：追踪戊型肝炎病毒的路径。
Virol J. 2024 Aug 23;21(1):194. doi: 10.1186/s12985-024-02470-3.
5
Hepatitis E virus: from innate sensing to adaptive immune responses.戊型肝炎病毒：从先天感应到适应性免疫反应。
Nat Rev Gastroenterol Hepatol. 2024 Oct;21(10):710-725. doi: 10.1038/s41575-024-00950-z. Epub 2024 Jul 22.
6
Identification of interferon-stimulated genes with modulated expression during hepatitis E virus infection in pig liver tissues and human HepaRG cells.鉴定在猪肝组织和人 HepaRG 细胞感染戊型肝炎病毒期间表达受调控的干扰素刺激基因。
Front Immunol. 2023 Nov 20;14:1291186. doi: 10.3389/fimmu.2023.1291186. eCollection 2023.
7
Three Distinct Reporter Systems of Hepatitis E Virus and Their Utility as Drug Screening Platforms.三种不同的戊型肝炎病毒报告系统及其作为药物筛选平台的应用。
Viruses. 2023 Sep 23;15(10):1989. doi: 10.3390/v15101989.
8
The Re-Emergence of Hepatitis E Virus in Europe and Vaccine Development.戊型肝炎病毒在欧洲的再现与疫苗研发。
Viruses. 2023 Jul 16;15(7):1558. doi: 10.3390/v15071558.
9
The Diagnosis, Pathophysiology, and Treatment of Chronic Hepatitis E Virus Infection-A Condition Affecting Immunocompromised Patients.慢性戊型肝炎病毒感染的诊断、病理生理学及治疗——一种影响免疫功能低下患者的病症
Microorganisms. 2023 May 16;11(5):1303. doi: 10.3390/microorganisms11051303.
10
Treatment Options for Hepatitis A and E: A Non-Systematic Review.甲型和戊型肝炎的治疗选择：非系统性综述。
Viruses. 2023 Apr 28;15(5):1080. doi: 10.3390/v15051080.